Jun 29, 2026 07:30AM
Apr 21, 2026 08:37AM
Apr 21, 2026 06:52AM
Apr 9, 2026 08:00AM
Mar 27, 2026 06:14AM
Mar 22, 2026 09:19PM
Mar 20, 2026 12:13PM LEQEMBI shows high treatment persistence in real-world study
Mar 20, 2026 12:05PM
Mar 10, 2026 10:07PM
Mar 10, 2026 07:30PM
Mar 1, 2026 06:49PM
Feb 9, 2026 10:34PM
Jan 25, 2026 11:52PM
Jan 25, 2026 08:37PM FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 25, 2026 06:30PM
Jan 25, 2026 06:30PM
Nov 26, 2025 06:03AM
Nov 26, 2025 04:42AM
Nov 25, 2025 07:31AM
Nov 25, 2025 07:30AM
Jul 30, 2025 11:00AM Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Jul 30, 2025 09:00AM
Jul 30, 2025 08:07AM
Jul 16, 2025 12:50AM
Mar 4, 2025 02:22AM
Jan 27, 2025 06:46PM
Jan 26, 2025 06:30PM
Jan 14, 2025 07:03PM FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 13, 2025 07:03PM
Oct 31, 2024 11:56PM
Oct 31, 2024 08:03PM
Aug 5, 2024 11:15PM
Jun 10, 2024 04:50AM
Jun 9, 2024 07:30PM
Jun 11, 2023 08:13PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 9, 2023 06:45PM
Jun 7, 2023 11:32PM
May 19, 2023 08:20PM
May 15, 2023 07:27PM
Apr 3, 2023 11:23PM
Apr 3, 2023 07:30PM
Mar 31, 2023 12:55AM Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Mar 30, 2023 07:31PM
Mar 30, 2023 07:30PM
Mar 22, 2023 07:30PM
Mar 19, 2023 07:30PM
Mar 13, 2023 09:09PM
Mar 13, 2023 03:00PM
Mar 5, 2023 07:58PM FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's
Mar 5, 2023 06:30PM

15,609 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All